 |
|
Home | Jazz Pharmaceuticals, Inc. (JAZZ) Downgraded by Zacks Investment Research to “Neutral” |
 |
Jazz Pharmaceuticals, Inc. (JAZZ) Downgraded by Zacks Investment Research to “Neutral”
|
 |
- February 04, 2011
-
Equities research analysts at Zacks Investment Research downgraded shares of Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday. Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology [...]This article (Jazz Pharmaceuticals, Inc. (JAZZ) Downgraded by Zacks Investment Research to “Neutral”) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.
- Read more at:http://feedproxy.google.com/~r/AmericanBankingNews/~3/OWhOE-hPbS8/
|
 |
|
 |
|
 |
